PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $1,000 | -98.6% | 419 | -97.0% | 0.00% | – |
| Q4 2019 | $71,000 | +42.0% | 13,924 | +40.6% | 0.00% | – |
| Q3 2019 | $50,000 | -34.2% | 9,901 | -19.4% | 0.00% | – |
| Q2 2019 | $76,000 | +590.9% | 12,286 | +437.9% | 0.00% | – |
| Q1 2019 | $11,000 | +120.0% | 2,284 | +91.0% | 0.00% | – |
| Q4 2018 | $5,000 | +25.0% | 1,196 | +105.1% | 0.00% | – |
| Q3 2018 | $4,000 | 0.0% | 583 | +10.6% | 0.00% | – |
| Q2 2018 | $4,000 | -71.4% | 527 | -64.4% | 0.00% | – |
| Q1 2017 | $14,000 | -86.8% | 1,481 | -91.4% | 0.00% | – |
| Q4 2015 | $106,000 | +49.3% | 17,316 | +39.0% | 0.00% | – |
| Q3 2015 | $71,000 | -38.8% | 12,457 | -19.6% | 0.00% | – |
| Q2 2015 | $116,000 | +107.1% | 15,487 | +65.0% | 0.00% | – |
| Q1 2015 | $56,000 | +700.0% | 9,387 | +445.8% | 0.00% | – |
| Q2 2014 | $7,000 | – | 1,720 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |